Overall (N = 14,461)

Non-Squamous (N = 9,359)

Squamous (N = 2,527)

Unspecified Non-Small Cell Cancer (N = 471)

Not Documented (N = 2,104)

EGFR Status, N (%)

Patients tested

5132 (35.5)

4456 (47.6)

358 (14.2)

120 (25.5)

198 (9.4)

Negative

4098 (79.9)

3500 (78.5)

330 (92.2)

111 (92.5)

157 (79.3)

Positive1

1016 (19.8)

938 (21.1)

28 (7.8)

9 (7.5)

41 (20.7)

Tested, but result unknown

18 (0.4)

18 (0.4)

0

0

0

No documented testing

9329 (64.5)

4903 (52.4)

2169 (85.8)

351 (74.5)

1906 (90.6)

ALK Status, N (%)

Patients tested

4752 (32.9)

4121 (44.0)

337 (13.3)

119 (25.3)

175 (8.3)

Negative

4448 (93.6)

3849 (93.4)

322 (95.5)

111 (93.3)

166 (94.9)

Positive

204 (4.3)

189 (4.6)

8 (2.4)

1 (0.8)

6 (3.4)

Tested, but result unknown

100 (2.1)

83 (2.0)

7 (2.1)

7 (5.9)

3 (1.7)

No documented testing

9709 (67.1)

5238 (56.0)

2190 (86.7)

352 (74.7)

1929 (91.7)

ROS1 Status, N (%)

Patients tested

820 (5.7)

712 (7.6)

91 (3.6)

15 (3.2)

2 (0.1)

Negative

797 (97.2)

690 (96.9)

91 (100.0)

14 (93.3)

2 (100.0)

Positive

23 (2.8)

22 (3.1)

0

1 (6.7)

0

No documented testing

13,641 (94.3)

8647 (92.4)

2436 (96.4)

456 (96.8)

2102 (99.9)

PD-L1 Status, N (%)

Patients tested

831 (5.7)

673 (7.2)

135 (5.3)

19 (4.0)

4 (0.2)

Negative

487 (58.6)

402 (59.7)

78 (57.8)

7 (36.8)

0

Positive

344 (41.4)

271 (40.3)

57 (42.2)

12 (63.2)

4 (100.0)

No documented testing

13,630 (94.3)

8686 (92.8)

2392 (94.7)

452 (96.0)

2100 (99.8)

BRAF Status, N (%)

Patients tested

16 (0.1)

15 (0.2)

0

1 (0.2)

0

Negative

13 (81.3)

13 (86.7)

0

0

0

Positive

3 (18.8)

2 (13.3)

0

1 (100.0)

0

No documented testing

14,445 (99.9)

9344 (99.8)

2527 (100.0)

470 (99.8)

2104 (100.0)